Noah Goodman
Chief Business OfficerMr. Noah Goodman, M.B.A., is Chief Business Officer of Kymera Therapeutics, Inc. from April 8, 2025. Mr. Goodman joined the Kymera Therapeutics, Inc. in April 8, 2025. Mr. Goodman was Senior Vice President of Business Development of Chroma Medicine, Inc. from September 2022. He joined Chroma Medicine, Inc. from Cadent Therapeutics, where, as Executive Director and Head of Business Development, he led Cadent’s acquisition by Novartis. Prior to Cadent Medicine, Inc., he was Head of Business Development at Seres Therapeutics, where he was responsible for leading collaborations and licensing transactions across several therapeutic areas including the Medicine, Inc.'s collaboration with AstraZeneca. He also worked in business development at Spark Therapeutics and as a management consultant at Easton Associates (now part of Navigant Consulting), a boutique life sciences consultancy, where he advised clients on corporate strategy and business development. He holds a B.S. in neuroscience from the University of Michigan and an M.B.A. from the Wharton School of the University of Pennsylvania.
Positions
- Company NameKymera Therapeutics, Inc.Stock CodeKYMRPositionChief Business OfficerColleagues
- NMNello MainolfiCo-Founder, President, CEO & Director
- FJFelix James BakerIndependent Chairman
- BNBruce N. JacobsChief Financial Officer
- BRBrian R. AdamsChief Legal Officer & Corporate Secretary
- JAJared A. GollobAdvisor
- JWJeffrey W. AlbersIndependent Director
- PEPamela EspositoIndependent Director
- EHElena H. RidloffIndependent Director
